Teachers Retirement System of The State of Kentucky Invests $564,000 in BridgeBio Pharma, Inc. $BBIO

Teachers Retirement System of The State of Kentucky bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 10,868 shares of the company’s stock, valued at approximately $564,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Corient Private Wealth LLC purchased a new stake in shares of BridgeBio Pharma during the 2nd quarter worth about $643,000. WINTON GROUP Ltd purchased a new position in BridgeBio Pharma in the second quarter valued at approximately $3,856,000. Principal Financial Group Inc. raised its holdings in BridgeBio Pharma by 23.0% in the third quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock valued at $65,829,000 after buying an additional 236,885 shares during the period. L & S Advisors Inc acquired a new position in BridgeBio Pharma during the third quarter valued at approximately $877,000. Finally, Federated Hermes Inc. lifted its position in BridgeBio Pharma by 53.0% during the third quarter. Federated Hermes Inc. now owns 424,695 shares of the company’s stock valued at $22,059,000 after buying an additional 147,108 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Positive Phase 3 BBP-418 data in LGMD2I/R9 strengthens the clinical and revenue upside narrative for BridgeBio’s rare-disease pipeline; that result is being argued as expanding the company’s long-term bull case. Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)?
• Positive Sentiment: Truist raised its price target to $95 and kept a Buy rating, citing recent commercial traction (pre-announced Attruby sales) — a notable analyst endorsement that can support investor confidence and boost valuation expectations. Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
• Positive Sentiment: Consensus analyst sentiment remains constructive (MarketBeat/AmericanBankingNews report a “Moderate Buy” consensus and an $82.50 average target), suggesting broad Wall Street support despite recent volatility. BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Reported short-interest data in the feed is inconsistent/unclear (entries show 0 shares and NaN changes), so there’s no clear signal from short-sellers to explain today’s move.
• Negative Sentiment: Director Andrea Ellis sold 64,921 shares (~$4.21M) on March 4, cutting her stake by ~77.7% — insider selling can be interpreted negatively by the market even when for personal/liquidity reasons. BridgeBio Pharma (NASDAQ:BBIO) Director Sells $4,211,425.27 in Stock
• Negative Sentiment: Recent quarterly results showed an EPS miss (reported ($1.00) vs. consensus ($0.75)), reminding investors that BridgeBio is still delivering mixed near-term financials despite big revenue improvements year-over-year.

Insider Buying and Selling

In related news, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $74.26, for a total value of $148,520.00. Following the transaction, the chief accounting officer owned 130,297 shares in the company, valued at approximately $9,675,855.22. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total value of $2,877,600.00. Following the completion of the transaction, the chief executive officer owned 695,686 shares in the company, valued at approximately $50,047,650.84. This trade represents a 5.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 229,095 shares of company stock worth $16,247,760 over the last quarter. Company insiders own 18.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BBIO shares. Truist Financial increased their price objective on shares of BridgeBio Pharma from $86.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. HC Wainwright lifted their target price on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Barclays initiated coverage on BridgeBio Pharma in a research report on Wednesday, January 28th. They issued an “overweight” rating on the stock. Finally, Morgan Stanley boosted their price objective on BridgeBio Pharma from $96.00 to $98.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Twenty-two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $82.50.

BridgeBio Pharma Trading Down 1.2%

NASDAQ BBIO opened at $65.36 on Friday. The stock has a market cap of $12.67 billion, a P/E ratio of -17.29 and a beta of 1.13. The company’s fifty day simple moving average is $73.64 and its 200-day simple moving average is $65.34. BridgeBio Pharma, Inc. has a 52 week low of $28.33 and a 52 week high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The company had revenue of $154.18 million for the quarter, compared to analyst estimates of $150.71 million. During the same period last year, the firm posted ($1.40) earnings per share. The company’s quarterly revenue was up 2521.2% on a year-over-year basis. On average, research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.